• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Symposium on Amyloidosis >HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDM/SCT) FOR TREATMENT OF AL AMYLOIDOSIS: TEN YEAR SINGLE INSTITUTIONAL EXPERIENCE
【24h】

HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDM/SCT) FOR TREATMENT OF AL AMYLOIDOSIS: TEN YEAR SINGLE INSTITUTIONAL EXPERIENCE

机译：高剂量素母蛋白和自体干细胞移植（HDM / SCT）用于治疗Al淀粉样症：十年单一制度经验

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In an effort to increase treatment responses for AL amyloidosis patients and improve organ function, quality of life, and survival, we and other centers have explored the safety and efficacy of HDM/SCT over the last 10 yrs. More than 700 pts have been evaluated for treatment with HDM/SCT on institutionally approved clinical trials at Boston Medical Center since 1994. 56% of evaluated patients met eligibility criteria for transplantation, and 363 patients have intitiated treatment. 330 transplants have been performed with an overall treatment related mortality of 13% and a complete hematologic response (CR) rate of 40%. With a median followup of >4 years, 54% of treated pts remain alive, and median survival exceeds 4 years. Survival and hematologic response is associated with improvement in organ function and in quality of life (QOL).
机译：为了增加对Al淀粉样蛋白病患者的治疗反应，提高器官功能，生活质量和生存，我们和其他中心探讨了HDM / SCT在过去10年内的安全性和功效。自1994年以来，已在机构批准的HDM / SCT治疗中评估了700多名以上的审核。56％的评估患者达到移植的资格标准，363名患者进行了侵染治疗。已经进行了330种移植，其整体治疗相关死亡率为13％，完全血液应答（Cr）率为40％。随着2岁的中间后续，54％的治疗PTS保持活力，中位生存率超过4年。存活和血液学反应与器官功能的改善和生活质量（QOL）有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号